A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease The EXECUTIVE Trial (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease)

被引：21

作者：

Ribichini, Flavio ^{[1
]}

Romano, Michele ^{[2
]}

Rosiello, Renato ^{[2
]}

La Vecchia, Luigi ^{[3
]}

Cabianca, Ester ^{[3
]}

Caramanno, Giuseppe ^{[4
]}

Milazzo, Diego ^{[4
]}

Loschiavo, Paolo ^{[5
]}

Rigattieri, Stefano ^{[5
]}

Musaro, Salvatore ^{[6
]}

Pironi, Bruno ^{[6
]}

Fiscella, Antonio ^{[7
]}

Amico, Francesco ^{[7
]}

Indolfi, Ciro ^{[8
,9
]}

Spaccarotella, Carmen ^{[8
]}

Bartorelli, Antonio ^{[9
]}

Trabattoni, Daniela ^{[9
]}

Della Rovere, Francesco ^{[10
]}

Rolandi, Andrea ^{[10
]}

Beqaraj, Federico ^{[11
]}

Belli, Riccardo ^{[11
]}

Sangiorgio, Pietro ^{[12
]}

Villani, Rosvaldo ^{[13
]}

Berni, Andrea ^{[14
]}

Sheiban, Imad ^{[15
]}

Quijada, Maria Jose Lopera ^{[16
]}

Cappi, Barbara ^{[16
]}

Ribaldi, Licia ^{[16
]}

Vassanelli, Corrado ^{[1
]}

机构：

[1] Univ Verona, Dept Med, I-37126 Verona, Italy

[2] Azienda Osped Carlo Poma, Mantua, Italy

[3] Osped San Bortolo, Vicenza, Italy

[4] Azienda Osped San Giovanni di Dio, Agrigento, Italy

[5] Osped Sandro Pertini, Rome, Italy

[6] Osped Gen Madre Vannini, Rome, Italy

[7] Azienda Osped Cannizzaro, Catania, Italy

[8] Magna Graecia Univ Catanzaro, Azienda Osped Mater Domini, Catanzaro, Italy

[9] IRCCS Ctr Cardiol Monzino, Milan, Italy

[10] Ente Osped Osped Galliera, Genoa, Italy

[11] Osped Maria Vittoria, Turin, Italy

[12] Osped Maggiore Bologna, Bologna, Italy

[13] Osped Vigevano, Azienda Osped Pavia & Prov, Vigevano, Italy

[14] Azienda Osped S Andrea, Rome, Italy

[15] Azienda Osped Univ Molinette San Giovanni Battist, Turin, Italy

[16] Abbott Vasc Knoll Ravizza SpA, Milan, Italy

来源：

JACC-CARDIOVASCULAR INTERVENTIONS | 2013年 / 6卷 / 10期

关键词：

coronary artery disease; drug-eluting stent(s); multivessel disease; randomized clinical trial; BYPASS-SURGERY; FOLLOW-UP; LEFT MAIN; 3-VESSEL DISEASE; TASK-FORCE; SPIRIT III; ERACI-II; INTERVENTION; REVASCULARIZATION; LESIONS;

D O I：

10.1016/j.jcin.2013.05.016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives This study sought to investigate the efficacy and performance of the XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) in the treatment of de novo coronary lesions in patients with 2- to 3-vessel multivessel coronary artery disease (MV-CAD). Background Drug-eluting stents (DES) have emerged as an alternative to conventional coronary artery bypass surgery in patients with MV-CAD although first-generation DES yielded inferior efficacy and safety compared with surgery. Methods Prospective, randomized (1:1), multicenter feasibility trial was designed to assess angiographic efficacy of EES compared with the TAXUS paclitaxel-eluting stent (PES) in 200 patients, and a prospective, open-label, single-arm, controlled registry was designed to analyze the clinical outcome of EES at 1-year follow-up in 400 MV-CAD patients. For the randomized trial, the primary endpoint was in-stent late loss at 9 months. For the registry, the primary endpoint was a composite of all-cause death, myocardial infarction, and ischemia-driven target vessel revascularization at 12 months. Results The primary endpoint per single lesion was significantly lower in the EES group compared with the PES group (-0.03 +/- 0.49 mm vs. 0.23 +/- 0.51 mm, p = 0.001). Similar results were observed when analyzing all lesions (0.05 +/- 0.51 mm vs. 0.24 +/- 0.50 mm, p < 0.001). Clinical outcome at 1 year yielded a composite of major adverse cardiac events of 9.2% in the single-arm registry, and 11.1% and 16.5% in the EES and PES randomized groups, respectively (p = 0.30). Conclusions The EXECUTIVE trial was a randomized pilot trial dedicated to the comparison of the efficacy of 2 different DES among patients with 2- to 3-vessel MV-CAD. The study shows lower in-stent late loss at 9 months with the EES XIENCE V compared with the PES TAXUS Liberte, and a low major adverse cardiac event rate at 1 year in patients with 2- to 3-vessel MV-CAD. (EXECUTIVE [EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease]; NCT00531011) (J Am Coll Cardiol Intv 2013;6:1012-22) (C) 2013 by the American College of Cardiology Foundation

引用

页码：1012 / 1022

页数：11

共 50 条

[31] SPIRIT II STUDY: EVALUATION OF THE XIENCE V EVEROLIMUS ELUTING CORONARY STENT IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
Onuma, Yoshinobu
Serruys, Patrick W.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
[32] Evaluation Of Effectiveness And Safety Of Everolimus Eluting Stent System (XIENCE V) In Acute Coronary Syndrome Patients
Karakulak, U. N.
Yorgun, H.
Sahiner, L.
Kaya, B.
Kabakci, G.
Aytemir, K.
Oto, A.
AMERICAN JOURNAL OF CARDIOLOGY, 2014, 113 (07): : S3 - S3
[33] Clinical, angiographic, and IVUS results from the pivotal US randomized SPIRIT III trial of the XIENCE V everolimus eluting coronary stent system
Buellesfeld, L.
HERZ, 2007, 32 (03) : 248 - 248
[34] Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: Final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial
Brener, Sorin J.
Kereiakes, Dean J.
Simonton, Charles A.
Rizvi, Ali
Newman, William
Mastali, Kourosh
Wang, John C.
Caputo, Ronald
Smith, Robert S., Jr.
Ying, Shih-Wa
Cutlip, Donald E.
Stone, Gregg W.
AMERICAN HEART JOURNAL, 2013, 166 (06) : 1035 - 1042
[35] The SPIRIT V Diabetic Study: A randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions
Grube, Eberhard
Chevalier, Bernard
Guagliumi, Giulio
Smits, Peter C.
Stuteville, Marrianne
Dorange, Cecile
Papeleu, Peggy
Kaul, Upendra
Dzavik, Vladimir
AMERICAN HEART JOURNAL, 2012, 163 (05) : 867 - +
[36] Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions The SPIRIT II Trial
Claessen, Bimmer E.
Beijk, Marcel A.
Legrand, Victor
Ruzyllo, Witold
Manari, Antonio
Varenne, Olivier
Suttorp, Maarten J.
Tijssen, Jan G. P.
Miquel-Hebert, Karine
Veldhof, Susan
Henriques, Jose P. S.
Serruys, Patrick W.
Piek, Jan J.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (04) : 339 - 347
[37] Microarray Analysis for Nobori Biolimus A9 Eluting Stent and Xience V Everolimus Eluting Stent in Porcine Coronary Artery
Sumida, Arihiro
Natarajan, Selvamuthu
Panchal, Deepal
Li, Jinsheng
Hou, Dongming
Chronos, Nicholas
Singh, Jaipal
Chavan, Surendra
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (20) : B124 - B124
[38] Pharmacokinetic Sub-Study in the SPIRIT III Randomized and Controlled Trial of XIENCE V® Everolimus Eluting Coronary Stent System
Wang, Qing
Pierson, Wesley
Sood, Poornima
Bol, Cornelis
Cannon, Louis
Gordon, Paul
Saucedo, Jorge
Sudhir, Krishnankutty
JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2010, 23 (01) : 26 - 32
[39] Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents Insights From the Xience V Coronary Stent System Trials
Genereux, Philippe
Rutledge, David R.
Palmerini, Tullio
Caixeta, Adriano
Kedhi, Elvin
Hermiller, James B.
Wang, Jin
Krucoff, Mitchell W.
Jones-McMeans, Jennifer
Sudhir, Krishnankutty
Simonton, Charles A.
Serruys, Patrick W.
Stone, Gregg W.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (05)
[40] Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Xience V Everolimus-Eluting Coronary Stent
Torguson, Rebecca
Waksman, Ron
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (12): : 1624 - 1630

← 1 2 3 4 5 →